Funded Biotechnology Startups in Houston
Disclosed funding in this Houston biotechnology snapshot is dominated by one outlier: Solugen’s $350M Series C on 2021-09-09, which dwarfs the next-largest…
Disclosed funding in this Houston biotechnology snapshot is dominated by one outlier: Solugen’s $350M Series C on 2021-09-09, which dwarfs the next-largest disclosed amount in these rows ($214M on 2024-06-13, also Solugen). At the same time, the list shows a cluster around 2025–2026 entries (most recent 2026-06-12 through 2025-01-14), with multiple rounds in the $7M–$30M range: Goldenrod Therapeutics ($7M, 2026-06-04), Oorja Bio ($30M, 2026-05-19), and CNS Pharmaceutical ($23M, 2026-05-04), among others.
Stage classification is also uneven: 11 of 22 rows use “Series Unknown” and 1 row is “undisclosed” (Western Chemical Consulting, 2023-07-26). Most companies are based in Houston, Texas across all 22 rows, including repeated names (Solugen appears twice with $350M in 2021 and $214M in 2024; also listed again as “Series Unknown” in 2024-06-13). The 22 rows span 2021-02-16 (Iterion Therapeutics, $17M) through 2026-06-12 (PolyVascular, $50K).
Most recent rounds
22 shownRelated listings
Frequently asked
What are the outliers in disclosed round size, and how does the largest round compare to the rest of this Houston biotech list?
Solugen’s $350M disclosed round (Series C, 2021-09-09) is the clear top figure and is far above the next-largest disclosed amount, Solugen’s $214M (2024-06-13, listed as “Series Unknown”). Most other disclosed amounts sit well below those levels, including $127M for AlloVir (2022-07-27) and $90M for Alleviant Medical (2025-01-14).
Are the most recent closings clustered in a narrow time window?
Yes. Within the newest 90 days of the listing’s latest date (2026-06-12), there are multiple entries: PolyVascular ($50K, 2026-06-12), Goldenrod Therapeutics ($7M, 2026-06-04), and Oorja Bio ($30M, 2026-05-19), with CNS Pharmaceutical ($23M, 2026-05-04) also falling in the same late-spring window of 2026.
How often is stage information missing or labeled as “Series Unknown” in these rows?
Stage classification is incomplete for 11 of 22 rows labeled “Series Unknown,” plus one additional row with an “undisclosed” amount (Western Chemical Consulting on 2023-07-26). By contrast, identifiable stages like Seed and Series A still appear multiple times, such as Seed rounds for Goldenrod Therapeutics (Seed, 2026-06-04) and Cellvie (Seed, 2025-09-09).
Does this list concentrate on certain stages rather than being evenly spread across biotech funding rounds?
Seed and Series A show up repeatedly alongside “Series Unknown.” For example, Seed entries include Cellvie ($5M, 2025-09-09) and K2bio ($620K, 2023-08-01), while Series A appears for Oorja Bio ($30M, 2026-05-19) and Pranax ($17M, 2026-01-29). However, “Series Unknown” still accounts for the largest share of the rows (11/22).
Are there any entries that stand out as unusually small despite the overall funding range?
The smallest disclosed amount is K2bio’s $620K (Seed, 2023-08-01), while other sub-$1M amounts remain rare (e.g., Pulmotect is $300K on 2023-06-14). At the other end, multiple six- and seven-figure disclosed rounds appear—AlloVir’s $127M (2022-07-27) and Solugen’s $350M (2021-09-09) are the most prominent—creating a wide spread between the minimum and maximum disclosed figures.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.